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Commentary to Accompany ‘Cost and Effectiveness of Laser with Phlebectomies
Compared with Foam Sclerotherapy in Superﬁcial Venous Insufﬁciency. Early
Results of a Randomised Controlled Trial’
J.R. Schneider*
Northwestern University, Vascular and Interventional Program of Central DuPage Hospital, Outpatient Services Building, 25 North Winﬁeld Road, Winﬁeld, IL 60190, United StatesDr. Lattimer and colleagues have presented the results of what
appears to be a well designed randomized study comparing ultra-
sound guided foam sclerotherapy to endovenous laser ablation of
the great saphenous vein and stab phlebectomy, adequately pow-
ered based on precedent estimates. The analysis and presentation
are clear. However, I am struck by the high rate of persistent and/or
recurrent reﬂux in the axial great saphenous vein in the EVLA. Their
observation that 26% of subjects in the laser arm of the study had
reﬂux at 3 months is much greater than any previous study. In
general the rate of reﬂux in those precedent studies is 10% or less
even at two years and the authors cite a metaanalysis with a ﬁgure
of 4.6% at 5 years. Their results with foam sclerotherapy seem
consistent with the precedent literature. Indeed power calculations
at the time of study acknowledged these precedents. On further
consideration of this study compared to the precedent articles it
occurs to me that it is possible that this may reﬂect a stricter
deﬁnition of hemodynamic success than was the case in the
precedent articles. As Dr. Lattimer points out he and colleagues
deﬁne failure as the presence of reﬂux in any segment of the above
knee great saphenous vein, whereas the precedent articles may
have graded a procedure as a success if reﬂuxwas no longer present
in the saphenofemoral junction and adjacent upper great saphe-
nous vein. If indeed the precedents used amore forgiving deﬁnition
for hemodynamic treatment failure then readers must decide
whether reﬂux in a segment of the great saphenous vein despite
occlusion (and no reﬂux) in the saphenofemoral junction andDOI of original article: 10.1016/j.ejvs.2012.01.032.
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doi:10.1016/j.ejvs.2012.03.002adjacent upper great saphenous vein should qualify as a failure of
the procedure. I would add that more than half of UFGS subjects
underwent repeat UGFS during the follow-up period, although the
originally targeted above knee axial great saphenous was retreated
in only 16% of UGFS subjects. The study was funded by the supplier
of the sclerosant, but other than allowing repeat UGFS during the
follow-up period I see nothing in the experimental design that
would suggest bias in the determination of effectiveness.
With respect to the analysis of costs the inclusion of stab
phlebectomy with EVLA certainly adds to time and indirectly to the
cost associated with the initial procedure. Repeat treatment in the
foam sclerotherapy group during the follow-up period also
confounds the analysis. Nevertheless the cost of disposables will
undoubtedly always be greater for endovenous ablation than for
foam sclerotherapy. Furthermore foam sclerotherapy avoids the
initial cost of buying the generator, safety glasses, and other items
necessary for laser ablation. I have no doubt that foam scle-
rotherapy will always be cheaper than endovenous thermal abla-
tion unless the cost of the sclerosant rises dramatically.
I congratulate the authors on an interesting and well analyzed
study. Their results imply that foam sclerotherapy is competitive as
measured by effectiveness with endovenous laser and by extrapo-
lation radiofrequency thermal ablation of the axial great saphenous
vein and that it is undoubtedly cheaper. However, as noted above, it
will be important to try to explain why their results with EVLA are
so discrepant from the precedents.d by Elsevier Ltd. All rights reserved.
